Skip to main content
. Author manuscript; available in PMC: 2020 Dec 3.
Published in final edited form as: Liver Int. 2018 Feb;38(Suppl 1):7–13. doi: 10.1111/liv.13673

FIGURE 1.

FIGURE 1

(A) Direct-acting antiviral agents (DAAs) with different mode of actions. HCV is curable with many DAAs available that specifically target the HCV virus replication cycle to inhibit replication (NS3 protease inhibitors, nucleoside/nucleotide analogues and non-nucleoside inhibitors of the RNA-dependent RNA polymerase and NS5A inhibitors). (B) Development milestones of approved direct-acting antiviral agents. DCV, daclatasvir; DSV, dasabuvir; EBV, elbasvir; GLE, glecaprevir; GRZ, grazoprevir; LDV, ledipasvir; OMV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; RTV, ritonavir; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir